Posted by Michael Wonder on 30 Aug 2021
Evrysdi (risdiplam) receives CADTH reimbursement recommendation for some patients with spinal muscular atrophy
30 August 2021 - Roche Canada today announced that the CADTH Canadian Drug Expert Committee has issued its final recommendation for Evrysdi (risdiplam) for treatment of spinal muscular atrophy for public reimbursement, with conditions, outside Quebec.
The recommendation states that Evrysdi should be reimbursed for spinal muscular atrophy patients if certain conditions are met.
